JP2013516482A5 - - Google Patents

Download PDF

Info

Publication number
JP2013516482A5
JP2013516482A5 JP2012548137A JP2012548137A JP2013516482A5 JP 2013516482 A5 JP2013516482 A5 JP 2013516482A5 JP 2012548137 A JP2012548137 A JP 2012548137A JP 2012548137 A JP2012548137 A JP 2012548137A JP 2013516482 A5 JP2013516482 A5 JP 2013516482A5
Authority
JP
Japan
Prior art keywords
composition
dexmedetomidine
pharmaceutically acceptable
pharmaceutical composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012548137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/020462 external-priority patent/WO2011085162A2/en
Publication of JP2013516482A publication Critical patent/JP2013516482A/ja
Publication of JP2013516482A5 publication Critical patent/JP2013516482A5/ja
Pending legal-status Critical Current

Links

JP2012548137A 2010-01-08 2011-01-07 局所経皮用デクスメデトミジン組成物およびそれらの使用方法 Pending JP2013516482A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29344010P 2010-01-08 2010-01-08
US61/293,440 2010-01-08
PCT/US2011/020462 WO2011085162A2 (en) 2010-01-08 2011-01-07 Topical transdermal dexmedetomidine compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2013516482A JP2013516482A (ja) 2013-05-13
JP2013516482A5 true JP2013516482A5 (enExample) 2014-02-27

Family

ID=44306157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012548137A Pending JP2013516482A (ja) 2010-01-08 2011-01-07 局所経皮用デクスメデトミジン組成物およびそれらの使用方法

Country Status (10)

Country Link
US (1) US20130072532A1 (enExample)
EP (1) EP2521544A4 (enExample)
JP (1) JP2013516482A (enExample)
CN (1) CN102753169A (enExample)
AU (1) AU2011204315A1 (enExample)
CA (1) CA2786598A1 (enExample)
MX (1) MX2012007933A (enExample)
NZ (2) NZ703808A (enExample)
RU (1) RU2012133969A (enExample)
WO (1) WO2011085162A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858721C (en) 2011-12-11 2021-03-16 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
RU2015148910A (ru) * 2013-05-06 2017-06-13 Аллерган, Инк. Альфа-адренергические агонисты для лечения повреждения тканей
EP3054934B1 (en) * 2013-10-07 2024-05-22 Teikoku Pharma USA, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
RU2018105761A (ru) * 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
RU2648449C2 (ru) * 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
CN110604728A (zh) * 2013-10-07 2019-12-24 帝国制药美国公司 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
KR20210113439A (ko) * 2016-10-31 2021-09-15 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
CN107929234B (zh) * 2017-12-25 2021-07-23 温州医科大学附属第一医院 一种应用于烧伤创面修复的外用制剂膏体
ES3004544T3 (en) 2018-06-27 2025-03-12 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
WO2020222188A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
WO2020222192A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN113577556A (zh) * 2021-08-01 2021-11-02 武汉左点科技有限公司 一种用于阴道康复治疗的生物反馈电刺激方法及装置
CN117582424A (zh) * 2022-08-17 2024-02-23 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US20030022926A1 (en) * 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production

Similar Documents

Publication Publication Date Title
RU2012133969A (ru) Локальные трансдермальные композиции дексмедетомидина и способы их применения
CN111565716B (zh) 使用地匹福林的方法
JP5902628B2 (ja) 相乗的抗ウイルス組成物及びその使用
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
JP2008044951A5 (enExample)
JP2015513309A5 (enExample)
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
JP2014515373A5 (enExample)
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
ES3029560T3 (en) 5-amino-2,3-dihydro-1,4-phthalazinedione as glucocorticoid-sparing agent
JP2020524689A5 (enExample)
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
JP2012525358A5 (enExample)
EA201591768A1 (ru) Дозированные препараты в качестве модуляторов опиоидного рецептора
JP2016505050A5 (enExample)
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
RU2018143564A (ru) Карбоновая кислота, предназначенная для лечения/предупреждения заложенности носа
JP2019516797A5 (enExample)
US20250143905A1 (en) Topical treatment for anorectal disorders with and without seat cushion
JP6659819B2 (ja) 化学療法に関連する脱毛の軽減方法
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
CN102596194A (zh) 组合药物
AU2020369029B2 (en) Novel pediatric combination
EP4364812A3 (en) Intranasal administration of ketamine to cluster headache patients
RU2012114097A (ru) Терапевтический агент против хронической боли